Allergan’s Botox Migraine Review Extended Three Months by U.S. Regulators

Allergan’s Botox Migraine Review Extended Three Months by U.S. Regulators
Allergan Inc. said U.S. regulators extended by three months a review of its top product, the wrinkle-smoother Botox, for a new use as a migraine treatment.
Read more on Bloomberg

An Update On Targeted Therapy In Metastatic Renal Cell Carcinoma
UroToday.com – For many years the mainstay of treatment for metastatic renal cell carcinoma (RCC) was immunotherapy, with response rates of from 10% to 20%. An improved understanding of the molecular biology in RCC has led to the development of numerous targeted therapies. However, to date the best therapy has not yet been validated, but sequential and combination treatment appears promising …
Read more on Medical News Today